이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

복합 우울증 및 알코올 사용 장애에 대한 케타민 (KeDA)

2026년 11월 14일 업데이트: Andreas Wahl Blomkvist, University Hospital of North Norway

복합 우울증 및 알코올 사용 장애에 대한 케타민: 맹검 무작위 활성 위약 대조 시험(KeDA 시험)

The goal of this clinical trial is to investigate the effects of ketamine, in combination with standard inpatient addiction therapy, for adults with depression and alcohol use disorder. After screening and enrollment, participants will undergo baseline assessments of depression, measures of alcohol use and craving, as well as neurocognitive function. Participants will then be randomized to either ketamine (intervention) or midazolam (control). All participants will be admitted for standard inpatient addiction therapy while receiving ketamine or midazolam. Measures on safety, depression and alcohol use disorder will be repeatedly assessed during and after treatment. Final follow-up assessment is scheduled 6 months after baseline assessment.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

Depression and alcohol use disorder (AUD) often coexist and can create significant challenges for individuals seeking effective treatment. Traditional treatment approaches have shown limited success in addressing both conditions simultaneously. Ketamine has shown to have promising rapid antidepressant effects and a possible role in the treatment of substance use disorders. By targeting both depression and AUD simultaneously, ketamine has the potential to offer dual benefits, improving depressive symptoms while addressing alcohol cravings or consumption. Furthermore, rapid relief from depressive symptoms may enhance motivation for recovery, reduce the risk of relapse, and improve overall treatment engagement and outcomes. Although ketamine is generally considered safe when administered under medical supervision, the safety profile in individuals with comorbid depression and AUD needs further investigation. The overall objective of this study is to examine the safety and efficacy of ketamine on adults with depression and AUD that are admitted for standard inpatient addiction therapy.

The study will only include adults with at least moderate depression and alcohol use disorder as their primary substance use disorder that are admitted for inpatient addiction therapy. Participants that are unable to give informed consent or have contraindication(s) for ketamine will be excluded.

After screening and enrollment, participants will undergo baseline assessments with measures on depression (using Montgomery-Åsberg Depression Rating Scale (MADRS) and Beck Depression Inventory-II (BDI-II)), alcohol use (using Timeline Follow-Back method (TLFB)), alcohol craving (using Short version of Alcohol Craving Questionnaire (ACQ-Short) and Penn Alcohol Craving Scale (PACS)) and neurocognitive function (using Cambridge Neuropsychological Test Automated Battery (CANTAB)). Participants will then be randomized to intervention group or control group. The intervention group will receive ketamine as four single doses, given biweekly for two weeks. The control group will receive midazolam as active placebo. Participants will undergo several follow-up assessments after treatment (1-2 day(s), 1 week, 2 weeks and 4 weeks after treatment). Final follow-up assessment will be 6 months after baseline.

By using open questions and specific instruments for assessing adverse effects associated with ketamine (using modified version of Ketamine Side Effect Tool (mKSET)), the trial will assess the frequency, severity and duration of any adverse events and severe adverse events. All adverse events will be evaluated with regards to its causal relationship to ketamine. In addition, physician-assessed and patient-assessed tolerability will be registered. Changes in neurocognitive function from baseline will be assessed after treatment.

Changes in depression will be measured several times using rater-blinded MADRS-assessment and self-report instrument (BDI-II). Measures of alcohol use (TLFB), alcohol craving (ACQ-short and PACS), relapse risk and time until relapse will used as measures on alcohol use disorder following treatment. Several exploratory objectives will be examined, including changes in alcohol dependence severity (using Severity of Alcohol Dependence Questionnaire (SADQ)), changes in quality of life (using World Health Organizations brief quality of life questionnaire (WHOQOL-BREF)), changes in self-reported treatment effectiveness (using Treatment Effectiveness Assessment (TEA)) and changes in anxiety (using Generalized Anxiety Disorder scale (GAD-7)). Finally, data on the subjective experience of the treatment (using Ego Dissolution Inventory (EDI), Emotional Breakthrough Inventory (EBI) and Mystical Experience Questionnaire (MEQ30)) will be collected and used in a regression model with baseline measures to assess predictors of treatment response on measures of depression and AUD .

연구 유형

중재적

등록 (추정된)

34

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

      • Moss, 노르웨이, 1535
        • 아직 모집하지 않음
        • Department of Addiction Treatment, ØHT
        • 연락하다:
        • 수석 연구원:
          • Mina Piiksi Dahli, PhD, M.D.
      • Tromsø, 노르웨이
        • 모병
        • Department of Addiction, University Hospital of North Norway
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Please contact the project team for a full and detailed list of inclusion/exclusion criteria

Inclusion Criteria:

  • Currently abstinent from alcohol
  • At least moderate depression without psychotic features
  • Minimum Montgomery-Åsberg Depression Rating Scale (MADRS) of 20
  • Alcohol dependence
  • Admitted for inpatient addiction therapy at University Hospital of North Norway or Østfold Hospital Trust

Exclusion Criteria:

  • Intoxicated or in significant withdrawal from alcohol or drug use
  • Not able to give adequate informed consent
  • Current or past history of schizophrenia, schizophreniform disorder, paranoid delusional disorder, schizoaffective disorder
  • Current or historical diagnosis of schizophrenia in a first degree relative
  • Cardiovascular conditions: recent stroke (< 1 year from informed consent), recent myocardial infarction (< 1 year from informed consent), uncontrolled hypertension (>150/100 mm Hg) or recent arrhythmia (< 1 year from informed consent; clinically significant arrhythmia requiring treatment at hospital)
  • Liver (Child-Pughs Class C) or kidney (Creatinin clearance < 30 mL/min) failure
  • Heart failure (the New York Heart Association Functional Classification (NYHA) class III or IV)
  • Chronic respiratory failure (requiring long-term oxygen therapy (LTOT) and/or Global Initiative for Chronic Obstructive Lung Disease system (GOLD) stage 3 or higher)
  • Previous anaphylactic reaction to ketamine or midazolam
  • Illegal use of ketamine the last 6 months
  • Pregnancy or breastfeeding
  • Current or suspected increased intracranial pressure

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Intervention group

Ketamine, 0,8 mg/kg body weight, given as four single doses (biweekly for two weeks)

Four single-doses, given two times per week for two weeks Dose: 0,8 mg/kg body weight Route of administration: intravenous infusions over 40 minutes

활성 비교기: Control group

Midazolam, 0,8 mg/kg body weight, given as four single doses (biweekly for two weeks)

Four single-doses, given two times per week for two weeks Dose: 0,02 mg/kg body weight Route of administration: intravenous infusions over 40 minutes

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Depression
기간: Within 3 days after final treatment session

Change from baseline using rater-blinded Montgomery-Åsberg Depression Rating Scale (MADRS) (range 0-60; higher score indicate worse outcome)

Within 3 days after final treatment session

2차 결과 측정

결과 측정
측정값 설명
기간
Alcohol craving tonic
기간: Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session

Penn Alcohol Craving Scale (PACS) (range 0-30; higher score indicate worse outcome)

Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session
Alcohol craving phasic
기간: Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session

Alcohol Craving Questionnaire - Short version (ACQ-short) (range 12-84; higher score indicate worse outcome)

Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session
Depression response/remission
기간: Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session

Rates of response (50% or more reduction in MADRS from baseline) and remission (9 points or less in MADRS)

Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session
Relapse risk
기간: From baseline until 6 months after baseline

Incidence of relapse in each group (defined as two or more consecutive heavy drinking days)

From baseline until 6 months after baseline
Time until relapse
기간: From baseline until 3 and 6 months after baseline

Average time from final treatment session until relapse

From baseline until 3 and 6 months after baseline

기타 결과 측정

결과 측정
측정값 설명
기간
Duration of antidepressant effect (blinded-rater assessed)
기간: From baseline until 6 months after baseline

Change in Montgomery-Åsberg Depression Rating Scale (MADRS) (range 0-60; higher score indicate worse outcome)

From baseline until 6 months after baseline
Duration of antidepressant effect (self-report)
기간: From baseline until 6 months after baseline

Change in the Beck Depression Inventory-II (BDI-II) (Range 0-63; higher score indicate worse outcome)

From baseline until 6 months after baseline
Tolerability using the ketamine side effect tool (KSET)
기간: Up to 1 month

Physician-reported tolerability of each treatment session (good, moderate and poor)

Up to 1 month
Tolerability using the ketamine side effect tool (KSET)
기간: Up to 1 month

Patient-reported tolerability of each treatment session (good, moderate and poor)

Up to 1 month
Cambridge Neuropsychological Test Automated Battery (CANTAB): Stop Signal Task (SST); Spatial Working Memory (SWM) task; Intra-Extra Dimensional Shift (IED) task; Paired Associates Learning (PAL) task; Emotional Bias Task (EBT)
기간: Within 3 days after final treatment session

Assess within- and between-group changes in neurocognitive function from baseline to within three days from the final treatment session: SST (Range 0-1000; Lower score indicate better outcome); SWM (Range: 2-14; Lower score indicates better outcome); IED (Range: 0-402; Lower score indicates better outcome); PAL (Range: 0-70; Lower score indicates better outcome); EBT (Range: 0-15; Higher score indicates better outcome (more happy))

Within 3 days after final treatment session
Adverse reaction frequency
기간: Up to 6 months

Frequency of adverse reactions

Up to 6 months
Adverse reaction severity
기간: Up to 6 months

Number of mild, moderate and severe adverse reactions

Up to 6 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 연구 책임자: Ole K Grønli, Assoc Prof, University Hospital of North Norway
  • 수석 연구원: Andreas W Blomkvist, M.D., University Hospital of North Norway

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 1월 20일

기본 완료 (추정된)

2028년 7월 1일

연구 완료 (추정된)

2028년 7월 1일

연구 등록 날짜

최초 제출

2023년 7월 1일

QC 기준을 충족하는 최초 제출

2023년 10월 16일

처음 게시됨 (실제)

2023년 10월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 14일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 2022/484848(REK)
  • 2023-506052-24 (EudraCT 번호)
  • U1111-1293-2654 (기타 식별자: WHO UTN)
  • 2023 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Individual participant data will not be shared with external researchers because the participant information and consent form limits research access to those formally affiliated with the KeDA trial.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .